1. Home
  2. NTLA vs ACEL Comparison

NTLA vs ACEL Comparison

Compare NTLA & ACEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTLA
  • ACEL
  • Stock Information
  • Founded
  • NTLA 2014
  • ACEL 2009
  • Country
  • NTLA United States
  • ACEL United States
  • Employees
  • NTLA N/A
  • ACEL N/A
  • Industry
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • ACEL Services-Misc. Amusement & Recreation
  • Sector
  • NTLA Health Care
  • ACEL Consumer Discretionary
  • Exchange
  • NTLA Nasdaq
  • ACEL Nasdaq
  • Market Cap
  • NTLA 710.1M
  • ACEL 818.8M
  • IPO Year
  • NTLA 2016
  • ACEL N/A
  • Fundamental
  • Price
  • NTLA $8.12
  • ACEL $11.39
  • Analyst Decision
  • NTLA Buy
  • ACEL Strong Buy
  • Analyst Count
  • NTLA 19
  • ACEL 2
  • Target Price
  • NTLA $38.26
  • ACEL $16.00
  • AVG Volume (30 Days)
  • NTLA 3.2M
  • ACEL 482.9K
  • Earning Date
  • NTLA 05-08-2025
  • ACEL 05-05-2025
  • Dividend Yield
  • NTLA N/A
  • ACEL N/A
  • EPS Growth
  • NTLA N/A
  • ACEL N/A
  • EPS
  • NTLA N/A
  • ACEL 0.49
  • Revenue
  • NTLA $45,569,000.00
  • ACEL $1,253,067,000.00
  • Revenue This Year
  • NTLA N/A
  • ACEL $8.29
  • Revenue Next Year
  • NTLA N/A
  • ACEL $4.28
  • P/E Ratio
  • NTLA N/A
  • ACEL $23.20
  • Revenue Growth
  • NTLA N/A
  • ACEL 6.28
  • 52 Week Low
  • NTLA $5.90
  • ACEL $9.02
  • 52 Week High
  • NTLA $28.18
  • ACEL $12.96
  • Technical
  • Relative Strength Index (RSI)
  • NTLA 50.39
  • ACEL 59.51
  • Support Level
  • NTLA $7.21
  • ACEL $10.16
  • Resistance Level
  • NTLA $9.27
  • ACEL $11.69
  • Average True Range (ATR)
  • NTLA 0.61
  • ACEL 0.33
  • MACD
  • NTLA 0.02
  • ACEL 0.04
  • Stochastic Oscillator
  • NTLA 44.20
  • ACEL 76.88

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About ACEL Accel Entertainment Inc.

Accel Entertainment Inc is a distributed gaming and local entertainment operator in the United States. It is engaged in the installation, maintenance, operation, and servicing of gaming terminals and related equipment, redemption devices that disburse winnings and contain automated teller machine (ATM) functionality, and amusement devices in authorized non-casino locations such as restaurants, bars, taverns, convenience stores, liquor stores, truck stops, and grocery stores. The Company also operates stand-alone ATMs in gaming and non-gaming locations. It generates revenue from Net gaming, Amusement, Manufacturing, ATM fees, and others.

Share on Social Networks: